NICE wants more Lemtrada data

The U.K.'s NICE said it is "minded not to recommend" multiple sclerosis drug Lemtrada alemtuzumab from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) but the institute said it needs more in...